RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Inhaled levodopa in everyday care

Researchers are following the use of Inbrija for periods when regular Parkinson's medicine wears off.

Learning by observing or collecting information · Study reference: DRKS00040628

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported date)
2026-06-09

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age 18 years and over · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion criteria: · Adult patients with Parkinson’s disease and OFF episodes who are receiving stable therapy with levodopa and a dopa decarboxylase inhibitor (benserazide or carbidopa), · Inbrija®-naive patients for whom treatment with Inbrija® is indicated and for whom the decision to initiate treatment with Inbrija®, in accordance with the prescribing information, was made independently by the treating physician prior to study enrollment, · Patients who have the necessary understanding to recognize OFF symptoms and can prepare the inhaler themselves, or who have a caregiver who can prepare the inhaler for them when needed, •written informed consent Exclusion criteria: · Patients who, according to the contraindications listed in the prescribing information, must not be treated with Inbrija®, Patients who are currently participating in a clinical trial.
Full study name & original research details

Official study title

Life with Inbrija for Parkinson's patients with OFF episodes - non-interventional study - LIFE ON

Short title used by the registry

Life with Inbrija for Parkinson's patients with OFF episodes - non-interventional study

Original description

Intervention: Group 1: Patients with Parkinson’s disease and “OFF” episodes who are being treated with levodopa and a dopa decarboxylase inhibitor may use Inbrija® as needed for the intermittent treatment of episodic motor fluctuations (“OFF” episodes), as determined by their doctor. The observation period is 3 months. Primary outcome: Change in cumulative OFF time per day from baseline to week 12 (based on the physician-patient interview and data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV, item 4.3) Secondary outcome: • Duration, frequency, and types of OFF episodes • Frequency, timing, and duration of action of Inbrija® • Number of capsules per inhalation • Types of OFF episodes treated • Overall assessment of the efficacy and tolerability of Inbrija® • Overall assessment of onset of action and ease of use • Discontinuation of therapy • Parkinson's Disease Questionnaire-8 (PDQ-8 (Parkinson specific quality of life) The data is collected during physician-patient interviews and through patient diaries (activity diary, Inbrija® usage diary).

Conditions reported: G20;Parkinson disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Observational
Interventions
Group 1: Patients with Parkinson’s disease and “OFF” episodes who are being treated with levodopa and a dopa decarboxylase inhibitor may use Inbrija® as needed for the intermittent treatment of episodic motor fluctuations (“OFF” episodes), as determined by their doctor. The observation period is 3 months.
Phases
Not reported
Sponsor
Merz Therapeutics GmbH
Start date reported by registry
2026-06-09 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-14 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Georg Ebersbach · +493320422781 · ebersbach@kliniken-beelitz.de

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Germany

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.